Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBritish American Tobacco Regulatory News (BATS)

Share Price Information for British American Tobacco (BATS)

Share Price is delayed by 15 minutes
Get Live Data
4,404.00    84.00 (1.94%)
Bid:
4,423.00
Ask:
4,425.00
Spread: 2.00 (0.045%)
Market Cap: £95.19b
BATS Live PriceLast checked at - London Stock Exchange

Intraday British American Tobacco Share Chart

Directorate Change

14 Oct 2025 07:00

RNS Number : 1927D
British American Tobacco PLC
14 October 2025
 

British American Tobacco p.l.c. (the "Company" or "BAT")

 

14 October 2025 

 

Board Change

Matthew Wright will join the Board of British American Tobacco p.l.c. as an independent Non-Executive Director with effect from 1 November 2025 and will be appointed as a member of the Remuneration and Nominations Committees.

 

Matt has spent his career advising leading organisations on the recruitment, retention and development of senior talent to support transformation and growth. Between 1993 and 2013, Matt held roles at Russell Reynolds Associates including the role of Chief Executive, President and Member of the Board, Head of Asia and Europe, Member of the Global Executive Committee and Member of the Global Operating Committee. Prior to that Matt held various roles at Korn/Ferry International, Knight Wendling and Cripps Leadership Advisors (formerly Cripps Sears Ltd).

 

Commenting on the appointment, Luc Jobin, Chair of the Board, said: "I am pleased to welcome Matt Wright to our Board. Cultural transformation is critical to our sustainable future, and having laid the foundations, we are progressing well. Matt brings valuable experience in this area. He also brings extensive international experience across Asia, Europe and the US, having led and advised global organisations in different sectors through periods of growth and transformation. His proven leadership and strong people acumen will be valuable assets as BAT continues on its ambition to build a Smokeless World."

Matt currently serves as Non-Executive Director of Berry Bros. & Rudd Ltd, where he also chairs the Remuneration Committee, Chairman of Cripps Leadership Advisors and Chair Designate and Senior Advisor of Movemeon.

 

Enquiries:

Media Centre

press_office@bat.com | @BATplc

Investor Relations

Victoria Buxton | IR_team@bat.com

 

Additional information

1. This announcement is made in compliance with the Company's obligations under UKLR 6.4.6.

2. In accordance with the Listing Rules, Matthew Wright has not been a director of any publicly quoted companies in the previous five years.

There are no additional matters that would require disclosure under UKLR 6.4.8 in respect of this appointment.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAGPGRAUUPAPUW
Date   Source Headline
25th Mar 20247:00 amRNSTransaction in Own Shares
22nd Mar 202410:40 amRNSDirector/PDMR Shareholding
22nd Mar 202410:35 amRNSDirector/PDMR Shareholding
22nd Mar 202410:30 amRNSDirector/PDMR Shareholding
22nd Mar 20247:00 amRNSTransaction in Own Shares
21st Mar 20243:26 pmRNSDirector/PDMR Shareholding
21st Mar 20243:20 pmRNSDirector/PDMR Shareholding
21st Mar 20247:00 amRNSTransaction in Own Shares
20th Mar 20247:00 amRNSTransaction in Own Shares
19th Mar 20247:00 amRNSTransaction in Own Shares
18th Mar 20247:00 amRNSShare Buy-Back Programme
14th Mar 20248:00 amRNSNotice of AGM
13th Mar 20247:00 amRNSCompletion of Block Trade of ITC Shares
12th Mar 20243:40 pmRNSDirector/PDMR Shareholding
12th Mar 202411:25 amRNSLaunch of Proposed Block Trade of ITC Shares
11th Mar 20244:43 pmRNSResponse to Recent Speculation
11th Mar 20247:00 amRNSBranch Register: Dividend Finalisation Information
7th Mar 20242:20 pmRNSDirector/PDMR Shareholding
5th Mar 20244:30 pmRNSPublication of a Prospectus
4th Mar 20242:15 pmRNSDirector/PDMR Shareholding
1st Mar 202410:45 amRNSDirector/PDMR Shareholding
1st Mar 202410:40 amRNSTotal Voting Rights
21st Feb 202410:45 amRNSDirector/PDMR Shareholding
16th Feb 202411:30 amRNSPricing Notes Offering
15th Feb 20242:55 pmRNSDirector/PDMR Shareholding
13th Feb 20241:30 pmRNSPublication of Suppl.Prospcts
13th Feb 20249:55 amRNSDirector/PDMR Shareholding
9th Feb 20244:17 pmRNSAnnual Financial Report
8th Feb 202412:15 pmRNSDirector/PDMR Shareholding
8th Feb 20247:00 amRNSFinal Results
6th Feb 202410:10 amRNSDirector/PDMR Shareholding
6th Feb 202410:05 amRNSDirector/PDMR Shareholding
6th Feb 20247:00 amRNSBoard and Committee Changes
5th Feb 202412:25 pmRNSDirector/PDMR Shareholding
5th Feb 202412:20 pmRNSDirector/PDMR Shareholding
5th Feb 202412:15 pmRNSDirector/PDMR Shareholding
2nd Feb 202412:00 pmRNSBAT and PMI Announce Global Patent Settlement
1st Feb 202412:45 pmRNSTotal Voting Rights
15th Jan 20242:00 pmRNSDirector/PDMR Shareholding
4th Jan 202412:30 pmRNSDirector/PDMR Shareholding
2nd Jan 202411:10 amRNSBlock listing Interim Review
2nd Jan 202410:15 amRNSTotal Voting Rights
19th Dec 20234:45 pmRNSHolding(s) in Company
12th Dec 20237:00 amRNSBranch Register: Dividend Finalisation Information
11th Dec 202310:35 amRNSHolding(s) in Company
11th Dec 202310:30 amRNSDirector/PDMR Shareholding
7th Dec 20233:30 pmRNSDirector/PDMR Shareholding
7th Dec 20233:30 pmRNSDirector/PDMR Shareholding
6th Dec 20237:55 amRNSPre-Close Trading Update and Strategy Update
6th Dec 20237:00 amRNSPre-Close Trading Update and Strategy Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.